EU/3/10/783

About

Please note that this product (marketed as Elocta) was withdrawn from the Community Register of designated orphan medicinal products in October 2015 at the request of the sponsor, at the time of the granting of a marketing authorisation.

On 20 September 2010, orphan designation (EU/3/10/783) was granted by the European Commission to Biogen Idec Limited, United Kingdom, for recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 for the treatment of haemophilia A.

This medicine is now known as efmoroctocog alfa.

Key facts

Active substance
Recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 (efmoroctocog alfa)
Medicine name
Elocta
Disease / condition
Treatment of haemophilia A
Date of decision
20/09/2010
Outcome
Withdrawn
Orphan decision number
EU/3/10/783

Review of designation

Please note that this product (marketed as Elocta) was withdrawn from the Community Register of designated orphan medicinal products in October 2015 at the request of the sponsor, at the time of the granting of a marketing authorisation.

Sponsor's contact details

Biogen Idec Limited
Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom
Tel. +44 (0)1628 501 000
Fax +44 (0)1628 501 010
E-mail: ukreception@biogenidec.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating